Inferra AIResearch Tools

Inferra AI / Company / INCY

Incyte

INCY · Health Care

Last earnings Oct 29, 2026

Key results

Total revenuequarter

$1.56 billion

Provides Business Updates Total revenue of $1.56 billion and total net sales of $1.32 billion in the third quarter of 2026, each an increase of 14% compared to the third quarter of 2025 Jakafi Jakafi XR (ruxolitinib) net sales of $827 million

SEC original ↗Incyte — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Revenuequarter

$1.32 billion

Provides Business Updates Total revenue of $1.56 billion and total net sales of $1.32 billion in the third quarter of 2026, each an increase of 14% compared to the third quarter of 2025 Jakafi Jakafi XR (ruxolitinib) net sales of $827 million

SEC original ↗Incyte — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Third Quarter 2026 Results Total revenue Total revenue was $1.56 billion, an increase of 14% compared to the third quarter of 2025, primarily driven by an increase in total net sales across marketed products.

SEC original ↗Incyte — Earnings release (8-K exhibit)EX-99Oct 29, 2026

GAAP operating incomequarter

18%

Excluding the Vega acquisition upfront consideration, GAAP operating income increased 18% primarily driven by growth in total revenue.

SEC original ↗Incyte — Earnings release (8-K exhibit)EX-99Oct 29, 2026

AI analysis

Q3 2026 · reported Oct 29, 2026

Based on: Earnings release + parent 8-K — transcript not held

Total revenue · Q3 2026
$1.56B
EX-99 · Oct 29, 2026
Revenue · Q3 2026
$1.32B
-21.0% vs prior quarter computed from stated figures
EX-99 · Oct 29, 2026

The quarter in charts

Guidance ladder — revenue

Delivered vs the company's guided range

EX-99 · Oct 29, 2026 Guide as stated by the company; range and midpoint computed from the stated figure.

Headline figures

MetricQ3 2026Prior qtrYear ago
Total revenue$1.56 billion$1.67 billion—
Revenue$1.32 billion$1.67 billion—
GAAP operating income18%——

EX-99 · Oct 29, 2026

Guidance · company-stated

Direction: Raised

Revenue$1,120 million

“2026 Financial Guidance Incyte is raising its full year 2026 net sales guidance for Opzelura to $1,100 - $1,120 million, Hematology and Oncology to $890 - $910 million and total net sales to $5,210 - $5,300 million to reflect continued strong performance across the portfolio.”

Company outlook — Reiterated

“Incyte is reaffirming its full year 2026 guidance for all other categories.”

Midpoint vs latest-quarter revenue-28.2%computed from stated figures

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

What changed vs last quarter

  • Guide midpoint vs latest-quarter revenue -28.2% computed from stated figures

Company-stated claims

Oct 29, 2026

Historical · increase of 254% · other

“Research and development expenses GAAP and Non-GAAP research and development expenses for the quarter ended September 30, 2026 were $1.79 billion and $1.75 billion, an increase of 254% and 274%, respectively, compared to the same period in 2025, primarily driven by the upfront consideration associated with the Vega acquisition, increased investment in latarcibart and continued advancement of our late stage development portfolio.”

EX-99 · Oct 29, 2026
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Third Quarter 2026 Results Total revenue Total revenue was $1.56 billion, an increase of 14% compared to the third quarter of 2025, primarily driven by an increase in total net sales across marketed products

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

Direction: Raised

Revenue: “2026 Financial Guidance Incyte is raising its full year 2026 net sales guidance for Opzelura to $1,100 - $1,120 million, Hematology and Oncology to $890 - $910 million and total net sales to $5,210 - $5,300 million to reflect continued strong performance across the portfolio.”

Revenue — Raised (“raising”)
“2026 Financial Guidance Incyte is raising its full year 2026 net sales guidance for Opzelura to $1,100 - $1,120 million, Hematology and Oncology to $890 - $910 million and total net sales to $5,210 - $5,300 million to reflect continued strong performance across the portfolio.”

Company outlook — Reiterated (“reaffirming”)
“Incyte is reaffirming its full year 2026 guidance for all other categories.”

Classified from the release's primary full-year outlook statement.

Strategy & priorities

INCA33890 (TGF R2xPD-1) Data from the ongoing Phase 1 trial presented at the 2026 ESMO Congress demonstrated encouraging clinical activity and a manageable safety profile of INCA33890 in combination with standard-of-care (SoC) chemotherapy and bevacizumab as a first-line treatment in patients with microsatellite-stable colorectal cancer (MSS CRC), supporting the ongoing Phase 3 study (NEXERA-303) and expansion of the program into earlier-stage disease.

SEC original ↗Incyte — Earnings release (8-K exhibit)EX-99Oct 29, 2026

INCB123667 (CDK2) As part of a strategic shift in focus toward the first-line maintenance ovarian cancer setting, enrollment in the Phase 3 study (MAESTRA-2) evaluating INCB123667 in patients with platinum-resistant ovarian cancer (PROC) was discontinued.

SEC original ↗Incyte — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises Hematology, Oncology and Inflammation and Autoimmunity.

SEC original ↗Incyte — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Risks & headwinds

2 Includes a one-time $246 million benefit related to our agreement with CMS to resolve our litigation related to the application of Medicaid rebate rules to Opzelura.

SEC original ↗Incyte — Earnings release (8-K exhibit)EX-99Oct 29, 2026

3 Opzelura net sales for the nine months ended September 30, 2026 include $246.0 million related to our agreement with CMS to resolve our litigation related to the application of Medicaid rebate rules to Opzelura.

SEC original ↗Incyte — Earnings release (8-K exhibit)EX-99Oct 29, 2026

8 Contract dispute settlement In May 2025, Incyte and Novartis entered into a settlement agreement with respect to litigation relating to the duration of royalty payments owed under the Collaboration and License Agreement between Incyte and Novartis.

SEC original ↗Incyte — Earnings release (8-K exhibit)EX-99Oct 29, 2026

What changed vs prior quarter

Guidance direction — prior quarter: Raised; this quarter: Raised

SEC original ↗Incyte — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Total revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Incyte — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care
Documents

Filings

33 documents

Earnings releases

9 documents

Presentations

0 documents

No presentations for Incyte are held in this edition of the library.

Transcripts

0 documents

No transcripts for Incyte are held in this edition of the library.

Mentioned by

3 companies

Other tracked companies whose held documents mention Incyte by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.